Innate Pharma SA

NASDAQ:IPHAUnited States

Nov 13, 2024

Show headlines and story abstract

• Press Release: Innate Pharma Reports Third Quarter 2024 Business Update and Financial Results, from 1:00AM ET on Wednesday Nov 13, 2024 by Dow Jones

  1:00AM ET on Wednesday Nov 13, 2024 by Dow Jones
  Companies Mentioned: IPHA
  
  Corporate update
  -- The Supervisory Board appointed Jonathan Dickinson as the Company's new Chief Executive Officer (CEO) and Chairman of the Executive Board, effective November 1, 2024. Jonathan Dickinson succeeds Hervé Brailly, co-founder of the Company, who was interim CEO, during the search process. Jonathan Dickinson most recently served as Executive Vice President and General Manager, Europe at Incyte, a role he held since 2016. Prior to Incyte, he gained significant leadership experience through several senior positions at ARIAD Pharmaceuticals, a US oncology focused biotechnology company and Bristol-Myers Squibb. This followed a distinguished 13-year tenure at Hoffmann-La Roche, where he was instrumental in driving the success of several of the company's flagship oncology therapies. Mr. Dickinson began his career at Novartis, holding roles of increasing responsibility within the oncology and endocrinology divisions. He holds a Bachelor of Science degree in Genetics and a Master of Business Administration from the University of Nottingham. -- The ATM program, pursuant to which it may, from time to time, offer and sell to eligible investors a total gross amount of up to $75 million of American Depositary Shares ("ADS") is still in place. As of September 30, 2024, no sales have been made under the program.
  

• Innate Pharma Reports Third Quarter 2024 Business Update and Financial Results, from 1:00AM ET on Wednesday Nov 13, 2024 by Dow Jones

  1:00AM ET on Wednesday Nov 13, 2024 by Dow Jones
  Companies Mentioned: IPHA
  
  Innate Pharma Reports Third Quarter 2024 Business Update and Financial Results
  -- Jonathan Dickinson appointed Chief Executive Officer and Chairman of the Executive Board -- Encouraging initial FDA feedback received on lacutamab regulatory pathway -- Lacutamab health-related quality of life and translational data to be presented at the upcoming ASH Annual Meeting -- IPH4502, a Nectin-4 ADC received FDA clearance of the IND to be developed in solid tumors -- Preclinical data for proprietary tetra-specific NK cell engager IPH6501 and novel ADC IPH4502 presented at SITC -- Cash position of EUR96.4 million1 as of September 30, 2024, anticipated cash runway to end of 2025 -- Conference call to be held today at 2:00 p.m. CET / 8:00 a.m. ET MARSEILLE, France--(BUSINESS WIRE)--November 13, 2024--